パゾパニブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "パゾパニブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

7nih.gov

4^th place

24^th place

6doi.org

2^nd place

6^th place

2glaxosmithkline.co.jp

low place

1medscape.com

719^th place

3,311^th place

1europa.eu

68^th place

425^th place

1medicines.org.uk

3,823^rd place

low place

1tga.gov.au

3,984^th place

low place

1pbs.gov.au

low place

1fiercebiotech.com

low place

1reuters.com

49^th place

67^th place

1gsk.com

low place

5,782^nd place

1pmda.go.jp

6,690^th place

394^th place

doi.org

Khurana V, Minocha M, Pal D, Mitra AK (March 2014). “Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.”. Drug Metabol Drug Interact. 0 (0): 1-11. doi:10.1515/dmdi-2013-0062. PMID 24643910.
Khurana V, Minocha M, Pal D, Mitra AK (May 2014). “Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.”. Drug Metabol Drug Interact. 0 (0): 1-11. doi:10.1515/dmdi-2014-0014. PMID 24807167.
Zivi, A; Cerbone, L; Recine, F; Sternberg, CN (September 2012). “Safety and tolerability of pazopanib in the treatment of renal cell carcinoma”. Expert Opinion on Drug Safety 11 (5): 851-859. doi:10.1517/14740338.2012.712108. PMID 22861374.
Verweij, J; Sleijfer, S (May 2013). “Pazopanib, a new therapy for metastatic soft tissue sarcoma”. Expert Opinion on Pharmacotherapy 14 (7): 929-935. doi:10.1517/14656566.2013.780030. PMID 23488774.
Schöffski, P (June 2012). “Pazopanib in the treatment of soft tissue sarcoma”. Expert Review of Anticancer Therapy 12 (6): 711-723. doi:10.1586/era.12.41. PMID 22716487.
Pick, AM; Nystrom, KK (March 2012). “Pazopanib for the treatment of metastatic renal cell carcinoma”. Clinical Therapeutics 34 (3): 511-520. doi:10.1016/j.clinthera.2012.01.014. PMID 22341567.

europa.eu

ema.europa.eu

“Votrient : EPAR - Product Information” (PDF). European Medicines Agency. Glaxo Group Ltd. (23 January 2014). 27 January 2014閲覧。

fiercebiotech.com

“Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer”. FierceBiotech (2008年9月15日). 2010年8月10日閲覧。

glaxosmithkline.co.jp

“新規抗がん剤「ヴォトリエント錠200mg」悪性軟部腫瘍の治療薬として日本で承認取得”. グラクソ・スミスクライン (2012年9月28日). 2015年3月29日閲覧。
“分子標的薬「ヴォトリエント錠」腎細胞がんに対する効能・効果で承認取得”. グラクソ・スミスクライン (2014年3月17日). 2015年3月29日閲覧。

gsk.com

“Regulatory update: Votrient (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU”. GlaxoSmithKline (31 March 2014). 7 April 2014閲覧。

medicines.org.uk

“Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)”. electronic Medicines Compendium. GlaxoSmithKline UK (20 December 2013). 27 January 2014閲覧。

medscape.com

reference.medscape.com

“Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. 27 January 2014閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Khurana V, Minocha M, Pal D, Mitra AK (March 2014). “Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.”. Drug Metabol Drug Interact. 0 (0): 1-11. doi:10.1515/dmdi-2013-0062. PMID 24643910.
Khurana V, Minocha M, Pal D, Mitra AK (May 2014). “Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.”. Drug Metabol Drug Interact. 0 (0): 1-11. doi:10.1515/dmdi-2014-0014. PMID 24807167.
Zivi, A; Cerbone, L; Recine, F; Sternberg, CN (September 2012). “Safety and tolerability of pazopanib in the treatment of renal cell carcinoma”. Expert Opinion on Drug Safety 11 (5): 851-859. doi:10.1517/14740338.2012.712108. PMID 22861374.
Verweij, J; Sleijfer, S (May 2013). “Pazopanib, a new therapy for metastatic soft tissue sarcoma”. Expert Opinion on Pharmacotherapy 14 (7): 929-935. doi:10.1517/14656566.2013.780030. PMID 23488774.
Schöffski, P (June 2012). “Pazopanib in the treatment of soft tissue sarcoma”. Expert Review of Anticancer Therapy 12 (6): 711-723. doi:10.1586/era.12.41. PMID 22716487.
Pick, AM; Nystrom, KK (March 2012). “Pazopanib for the treatment of metastatic renal cell carcinoma”. Clinical Therapeutics 34 (3): 511-520. doi:10.1016/j.clinthera.2012.01.014. PMID 22341567.

dailymed.nlm.nih.gov

“VOTRIENT (pazopanib hydrochloride) tablet, film coated [GlaxoSmithKline LLC]” (PDF). DailyMed. GlaxoSmithKline LLC (November 2013). 27 January 2014閲覧。

pbs.gov.au

“Pharmaceutical Benefits Scheme (PBS) - Pazopanib”. Pharmaceutical Benefits Scheme. Australian Government. 27 January 2014閲覧。

pmda.go.jp

info.pmda.go.jp

“ヴォトリエント錠200mg 添付文書” (2015年11月). 2016年7月2日閲覧。

reuters.com

uk.reuters.com

“GSK pulls bid to extend use of kidney drug to ovarian cancer”. Reuters (31 March 2014). 7 April 2014閲覧。

tga.gov.au

ebs.tga.gov.au

“PRODUCT INFORMATION VOTRIENT TABLETS” (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd (25 March 2013). 27 January 2014閲覧。